Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Actuate Therapeutics, Inc. ( (ACTU) ) has issued an update.
On September 10, 2025, Actuate Therapeutics, Inc. announced an underwritten public offering of 2,142,858 shares of common stock at $7.00 per share, with an expected closing date of September 11, 2025. The offering, managed by Lucid Capital Markets, LLC, is anticipated to generate gross proceeds of $15.0 million, which the company plans to use for working capital and general corporate purposes. The agreement includes a 30-day over-allotment option for the underwriter to purchase additional shares, and directors and executive officers have agreed to lock-up agreements restricting the sale of securities until December 9, 2025.
The most recent analyst rating on (ACTU) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Actuate Therapeutics, Inc. stock, see the ACTU Stock Forecast page.
More about Actuate Therapeutics, Inc.
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for high-impact, difficult-to-treat cancers. Their lead investigational drug, elraglusib, is a novel GSK-3β inhibitor targeting molecular pathways involved in tumor growth and resistance to conventional cancer treatments.
Average Trading Volume: 102,910
Technical Sentiment Signal: Strong Buy
Current Market Cap: $164.7M
Find detailed analytics on ACTU stock on TipRanks’ Stock Analysis page.